Cartesian Therapeutics, Inc. RNAC

RNAC Company Overview

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing RNA cell therapies for autoimmune diseases and oncology. The company operates within the biotechnology and advanced therapeutics industries, with a primary emphasis on engineered cell therapies designed to provide durable clinical responses while potentially reducing the toxicity and logistical complexity associated with conventional CAR-T approaches. Its lead programs have centered on messenger RNA (mRNA)-engineered cell therapies, particularly for autoimmune indications such as myasthenia gravis and related immune-mediated disorders.

The company evolved through a combination of biotechnology platform development and corporate restructuring activities, including the merger between Cartesian Therapeutics, Inc. and Selecta Biosciences, Inc., after which the combined company adopted the Cartesian Therapeutics name and continued trading under the ticker RNAC. Public filings, investor materials, and industry reporting indicate that Cartesian’s strategic positioning is based on transient RNA engineering technologies intended to avoid permanent genomic modification while enabling repeat dosing flexibility. The company primarily serves specialty healthcare markets through clinical-stage therapeutic development rather than commercial product sales.